

Persistent recalcitrant hypocalcemia following total thyroidectomy: a management challenge

Devesh Sanjeev Ballal, Kapil Tejaswy, Deviprasad Shetty,
Gabriel Rodrigues

Abstract

Hypocalcemia is the most common complication following total thyroidectomy and could be due to direct injury or ischemic damage to parathyroid glands during surgery. Hypocalcemia adds significantly to hospital stay and cost of hospitalisation. While there are numerous proposed treatment algorithms for post-thyroidectomy hypocalcemia, there are no universally accepted standard guidelines or treatment algorithms available. We present a case of prolonged recalcitrant hypocalcemia post-total thyroidectomy, requiring hospitalisation for more than a month, to illustrate the practical problems we faced during management of this patient.

Keywords

Hypocalcemia, thyroidectomy, calcium, parathormone.

Introduction

While hypocalcemia is the most common documented complication post-total thyroidectomy, hypocalcemia requiring prolonged hospitalisation and intravenous (IV) calcium supplementation is relatively rare. Hypocalcemia occurs due to manipulation of parathyroids during surgery, devascularisation, venous engorgement or accidental removal.¹ The incidence of temporary and permanent hypocalcemia is reported to be around 27% and 1% respectively.² Since the risk of reactionary/secondary haemorrhage after 24 hours of thyroidectomy is very rare, symptomatic hypocalcemia is the main reason for prolonged hospitalisation post-thyroidectomy.³

The pre-operative factors associated with post-thyroidectomy hypocalcemia are still unclear and various scoring systems have been proposed to identify patients likely to develop post-operative hypocalcemia.⁴ Identification of at-risk patients allows earlier and more aggressive calcium correction regimens allowing for shorter hospital stays and invasive investigations in low-risk patients.

Feeling of 'heat waves' are a documented adverse effect of IV calcium gluconate, especially when given rapidly. We could not find any literature linking either severe thrombophlebitis or high-grade fever with IV calcium injections. However, this is the second patient in our institute to develop high spiking fever coinciding with IV calcium injections.

Case report

A 39-year-old woman presented with thyromegaly and features suggestive of hyperthyroidism. She was worked up for the same

Devesh Sanjeev Ballal MBBS

Department of General Surgery,
Kasturba Medical College, Manipal University,
Manipal, India

Kapil Tejaswy MS

Department of General Surgery,
Kasturba Medical College, Manipal University,
Manipal, India

Deviprasad Shetty MS

Department of General Surgery,
Kasturba Medical College, Manipal University,
Manipal, India

Gabriel Rodrigues FRCS*

Department of General Surgery,
Kasturba Medical College, Manipal University,
Manipal, India
gabyrodricks@gmail.com

*Corresponding Author

Case Report

and diagnosed to have a multinodular goiter (MNG) with secondary thyrotoxicosis. Hyperthyroidism was controlled with carbimazole, thyroid status was optimised and patient was posted for total thyroidectomy. Intra-operatively, parathyroid glands were not identified and inferior thyroid artery branches were ligated and divided after crossing the recurrent laryngeal nerve (subcapsular vascular ligation). Intra-operative period was uneventful, patient was extubated and shifted to post-operative ward.

In the evening following thyroidectomy, patient complained of tingling in the fingers. On examination, Trousseau's sign was present (Figure).

Figure 1: Bilateral carpal spasm



Blood calcium levels were low, hence IV calcium gluconate bolus (10ml of 10% calcium gluconate in 100 ml 0.9% Saline) was given. Symptoms subsided but reappeared the next morning. Patient was started on thrice daily IV calcium boluses, however symptoms persisted and additional calcium boluses had to be given as needed. Patient also developed high spiking fever, for which she was worked up, and no evident source could be identified. Fever spikes coincided with IV calcium injections and patient developed pain and swelling around IV lines. A diagnosis of thrombophlebitis was made and IV lines were changed. Fever abated temporarily but reappeared the next day. IV lines were changed frequently and external jugular vein (EJV) cannulated but fever persisted. Oral calcitriol (0.25 mcg BD) and calcium carbonate was given (1.5 gm Q6H), supplemented with 6 glasses of milk daily. Phosphate and magnesium levels were assessed and found to be normal. Parathormone (PTH) was

assessed and found to be low (7.6 pg/ml; normal: 15-65pg/ml). Vitamin D levels were assessed and found to low (22.36 ng/ml; normal: >30 ng/ml). Histopathology examination of thyroidectomy specimen did not reveal any parathyroid tissue.

In view of frequent episodes of symptomatic hypocalcemia requiring additional IV calcium bolus, 1% IV calcium infusion (50 ml of 10% calcium gluconate in 450 ml saline) was started at 50 ml/hour. Though hypocalcemic episodes subsided, patient continued to have high spiking fever. Broad spectrum antibiotics were started and antipyretics were given. Fever abated for a few days, but reappeared. Patient developed episodes of symptomatic hypocalcemia whenever an attempt to taper calcium infusion was made. Hence treatment was altered: oral calcium reduced to 4g/day, oral calcitriol increased to 1.50 mcg (0.75mcg BD) daily, low dose hydrochlorothiazide (12.5 mg) added and salt restriction was advised. Calcium infusion was gradually tapered and stopped, and replaced with IV calcium boluses that were also gradually tapered and stopped. Patient did not have any further attacks of hypocalcemia or fever.

Patient was started on oral Vitamin D (60,000 IU once fortnightly), urine calcium and serum phosphate were assessed and calcitriol was reduced to 1.00 mcg/day and was discharged from the hospital after 46 days post-thyroidectomy.

Patient has since come for 5 follow-up visits. Serum calcium has stabilized and hence oral calcium supplementation was reduced. Calcitriol was gradually tapered and stopped. Oral Vitamin D was reduced to 60,000 IU monthly. Patient is currently doing well, with no constipation, fever or any symptoms suggestive of hypocalcemia.

Discussion

Severe hypocalcemia is one of the life-threatening complications post-thyroidectomy. The initial features of perioral numbness and tingling of fingers which often go unnoticed, can prove fatal due to cardiac arrest if prompt action is not taken at the appropriate moment.

Post-op hypocalcemia can be transient (lasting <12 months) or permanent, in which medical supplementation is required for more than 12 months⁹. Post-thyroidectomy hypocalcemia may be asymptomatic, termed 'lab hypocalcemia' or symptomatic. Symptomatic hypocalcemia, severe hypocalcemia (corrected calcium <7.5mg/dl, <1.87

Case Report

mmol/L) or hypocalcemia associated with ECG QT prolongation warrants hospitalisation and immediate IV calcium supplementation. Initial correction by bolus of 10 ml of 10% calcium gluconate in 50-100 ml 0.9% Saline/5% dextrose should be urgently administered in all cases of symptomatic hypocalcemia over 20 minutes, as more rapid infusion can cause lethal cardiac dysfunction.^{3,5} It is recommended that this be followed by IV calcium infusion regimen, as this bolus will only correct the calcium levels for 2-3 hours.⁶

Accurate prediction of which patients will develop this complication is difficult, leading to unnecessary long hospitalisation to monitor for this rather rare complication. A meta-analysis published by Edefe et al¹ identifies these factors as independent predictors of post-thyroidectomy hypocalcemia: (a) identification of <2 parathyroids during surgery; (b) reoperation for bleeding; (c) corrected calcium <7.5mg/dl or <1.87 mmol/L 24 hours post-surgery; (d) Graves' disease; (e) heavier thyroid specimens. An accurate risk stratification would allow for earlier and more aggressive institution of calcium correction regimens, possibly reducing hospital stay. This would also reduce unnecessary supplementation and investigations in the majority of patients who would not develop hypocalcemia. Albuja-Cruz et al⁴ have proposed a risk stratification protocol (Table 1). In this prospective study, the above-mentioned protocol was applied to 120 patients, demonstrating a significant reduction in calcium supplementation ($P \leq 0.001$) and hypocalcemic events ($P = 0.008$). However, this protocol requires routine measurement of pre-and post-operative PTH levels, an expensive test that may not be justified given the low incidence of persistent, severe hypocalcemia. Another prospective study by Arer et al⁵ on 106 patients demonstrated that routine calcium supplementation can prevent early hypocalcemia post-thyroidectomy. A retrospective study by Maxwell et al⁶ confirms that routine supplementation of calcium and Vitamin D were associated with reduced cost and duration of hospitalisation with fewer episodes of hypocalcemia.

Recalcitrant hypocalcemia patients not responding to conventional doses of active vitamin D analogues (calcitriol or 1-alpha calcidol) and oral calcium, and requiring prolonged IV calcium are

exceptionally rare. Treatment options for such patients include addition of thiazide diuretic and use of recombinant PTH. Thiazide diuretics also serve to offset the dose limiting side effect of Vitamin D and calcium supplementation: nephrocalcinosis due to increased renal calcium loss in the absence of the resorbptive effects of PTH on the renal tubules.⁷

Table 1: Proposed risk stratification protocol

Risk group	Recommended treatment
High risk: Post-op PTH <10 and/or fall in PTH more than 60% from pre-op value	Calcitriol 0.5 mcg BD + 6 g calcium daily
Intermediate risk: PTH 10-19 and/or corrected calcium <8	3 g calcium daily
Low risk: PTH >20 and/or corrected calcium >8	Nil

Recombinant PTH (rPTH) is expensive, and there are no controlled trials demonstrating its effectiveness or safety in the setting of post-thyroidectomy hypocalcemia. However, it has a lower incidence of hypercalciuria, significantly reduces calcium and calcitriol requirement. A prospective phase 2 randomised trial by McLeod et al⁸ on 26 patients demonstrated that rPTH may prevent post-thyroidectomy hypocalcemia, shorten duration of hospitalisation and reduce the need for calcium and Vitamin D on discharge. The drug label carries a warning for osteosarcoma although this has only been observed in rats, at a dose much higher than what is generally used in humans⁹. The cost of this injectable drug limits its use in clinical practice and it is only recommended for use in patients who cannot attain normocalcemia on oral calcium and Vitamin D supplements alone.⁹

All patients receiving active vitamin D analogues and calcium supplementation should have regular monitoring of serum calcium and phosphate levels, until values stabilise. The lowest dose required to achieve a low-normal serum calcium while avoiding hyperphosphatemia should be administered. Shorter acting calcitriol should be replaced with longer acting vitamin D analogues

such as cholecalciferol to simplify dosing. Also, urine calcium should be maintained less than 300 mg/24 hours to prevent nephrocalcinosis that can result in chronic kidney disease. This case highlights the significant morbidity and difficulty faced in managing a relatively simple complication. Accurate prediction and early institution of treatment could possibly reduce length of hospitalisation.

References

1. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. *Br J Surg.* 2014;101:307-20.
2. Docimo G, Ruggiero R, Casalino G, Del Genio G, Docimo L, Tolone S. Risk factors for postoperative hypocalcemia. *Updates Surg.* 2017 Apr 25. doi: 10.1007/s13304-017-0452-x.
3. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. *Endocrinol Metab Clin North Am.* 1993;22:363-75.
4. Albuja-Cruz MB, Pozdeyev N, Robbins S, Chandramouli R, Raeburn CD, Klopper J, et al. A 'safe and effective' protocol for management of post-thyroidectomy hypocalcemia. *Am J Surg.* 2015;210:1162-8.
5. Arer IM, Kus M, Akkapulu N, Aytac HO, Yabanoglu H, Caliskan K, et al. Prophylactic oral calcium supplementation therapy to prevent early post thyroidectomy hypocalcemia and evaluation of postoperative parathyroid hormone levels to detect hypocalcemia: A prospective randomized study. *Int J Surg.* 2017;38:9-14.
6. Maxwell AK, Shonka DC Jr, Robinson DJ, Levine PA. Association of preoperative calcium and calcitriol therapy with postoperative hypocalcemia after total thyroidectomy. *JAMA Otolaryngol Head Neck Surg.* 2017 Apr 13. doi: 10.1001/jamaoto.2016.4796.
7. Chandler PD, Scott JB, Drake BF, Ng K, Forman JP, Chan AT, et al. Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. *Am J Med.* 2014;127:772-8.
8. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, et al. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. *Thyroid.* 2006;16:259-65.
9. Stack BC Jr, Bimston DN, Bodenner DL, Brett EM, Dralle H, Orloff LA, et al. American association of clinical endocrinologists and American college of endocrinology disease state clinical review: postoperative hypoparathyroidism - definitions and management. *Endocr Practice.* 2015;21: 674-85.